Klein Hersh Recruits New CHRO for Disc Medicine
On January 16, 2026, executive search firm Klein Hersh, headquartered in Horsham, PA, announced the appointment of Lisa Amaya Price as the new Chief Human Resources Officer (CHRO) at Disc Medicine, Inc., a clinical-stage biopharmaceutical company based in Watertown, MA.
Disc Medicine is undergoing a significant growth phase as it moves toward commercialization. According to John Quisel, President and CEO of Disc Medicine, “As we move towards commercialization, we have meaningfully increased hiring to support these efforts, and Lisa will play a central role in building a strong, scalable organization by attracting, developing, and retaining exceptional talent across the business.” He added that her leadership will be vital in preparing the company for long-term success and operational excellence.
Lisa Amaya Price’s Extensive HR Background
Bringing over 25 years of experience in human resources and organizational leadership, Lisa Amaya Price has held pivotal roles at several leading life sciences companies. Most recently, she served as Senior Vice President and CHRO at Deciphera Pharmaceuticals, where she played a key role in the company’s integration into ONO Pharmaceuticals.
Before her tenure at Deciphera, she was the Chief People Officer at LGC Group, a global life science tools company with more than 4,000 employees. She has also held senior HR leadership positions at Scholar Rock and Takeda Pharmaceuticals, where she led talent selection and organizational design efforts during the acquisition of Shire Pharmaceuticals.
Earlier in her career, Ms. Amaya Price spent eight years at Biogen, culminating in her role as Senior Director of Human Resources for R&D. She also held HR leadership positions at Interpublic Group, Inc., Metro International S.A., and American Financial Systems, Inc.
“I am excited to join Disc at this pivotal time for the company,” said Amaya Price. “The opportunity to help build and scale a team while preparing to deliver a much-needed therapy to patients with significant unmet needs is incredibly motivating. I look forward to partnering across the organization to support our people and culture as we enter this next phase of growth.”
Disc Medicine’s Mission and Focus
Disc Medicine specializes in the discovery, development, and commercialization of novel treatments for serious hematologic diseases. The company is building a robust portfolio of potentially first-in-class therapeutic candidates. These candidates are designed to address a wide range of hematologic conditions by targeting fundamental biological pathways such as heme biosynthesis and iron homeostasis.
The company’s strategic focus aligns closely with its mission to meet the unmet needs of patients suffering from blood disorders. With Lisa Amaya Price onboard, Disc Medicine aims to strengthen its organizational structure and talent capabilities to support future growth and innovation.
About Klein Hersh
Founded in 1998, Klein Hersh is an executive search firm that has become a trusted partner to global pharmaceutical, biotech, and healthcare companies. The firm also collaborates with private equity and venture capital-backed businesses to identify top executive talent.
Some of Klein Hersh’s notable clients include Akero, Aktis Oncology, Apogee Therapeutics, ArchWell Health, Atlas Venture, Bain Capital Life Sciences, Biogen, Capital Rx, and ConcertAI. The firm’s extensive client list highlights its strong presence in the life sciences and healthcare sectors.
Other Recent Placements by Klein Hersh
In addition to the placement at Disc Medicine, Klein Hersh recently assisted in the recruitment of Timothy Noyes as the President and CEO of Newleos Therapeutics, a biotechnology firm based in Boston, MA. Mr. Noyes replaces David Donabedian, who was the founding CEO and will continue to serve as an advisor.
Dr. Christoph Westphal, Executive Chair of Newleos and a founding partner at Longwood Fund, praised the transition: “Tim brings an exceptional track record of company building, fundraising, and advancing innovative therapies through early and late-stage development and commercialization.”
Mr. Noyes has over 30 years of experience leading biopharmaceutical companies through critical phases. Most recently, he was CEO of Aerovate Therapeutics, where he led the company through a successful IPO and advanced its lead program for pulmonary arterial hypertension through a global Phase 2/3 trial.
Looking Ahead
With experienced leaders like Lisa Amaya Price and Timothy Noyes joining key biopharmaceutical companies, the talent landscape in the life sciences industry continues to evolve. Klein Hersh’s role in these high-level placements highlights the firm’s influence and commitment to shaping the future of healthcare and biopharma leadership.
This article is inspired by content from Original Source. It has been rephrased for originality. Images are credited to the original source.
